Immunology

Top Story

FDA awards $18 million to fund trials of medical products for rare diseases

FDA awards $18 million to fund trials of medical products for rare diseases
September 29, 2018
FDA News

FDA approves Rituxan for pemphigus vulgaris

June 8, 2018
The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease that affects the skin…
Meeting News

IAS 2018: Advances, collaboration in immune-mediated inflammatory diseases

April 26, 2018
BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with immune-mediated…
FDA News

FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

April 6, 2018
The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a proposed trastuzumab…
More Headlines »
Healio Jobs